Research suggests that emergency response personnel, recovery workers, law enforcement, and construction workers who reported to the World Trade Center disaster site were exposed to carcinogens that doubled their risk of developing myeloma.
The EU has approved Sarclisa (isatuximab-irfc) in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant, based on data from the IMROZ phase III study.
